Kymera Therapeutics’ (KYMR) Overweight Rating Reiterated at Stephens

Stephens restated their overweight rating on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $60.00 target price on the stock.

A number of other research firms have also commented on KYMR. Leerink Partners reissued an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Friday, December 27th. Morgan Stanley increased their price objective on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. Truist Financial reaffirmed a “buy” rating and issued a $53.00 target price (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. BTIG Research started coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target on the stock. Finally, BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $55.06.

Kymera Therapeutics Stock Performance

KYMR opened at $44.23 on Tuesday. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -18.90 and a beta of 2.19. The firm’s 50-day simple moving average is $42.62 and its 200-day simple moving average is $44.65. Kymera Therapeutics has a twelve month low of $29.24 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.01. The firm had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company’s quarterly revenue was down 20.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.90) earnings per share. As a group, sell-side analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the sale, the insider now owns 54,826 shares of the company’s stock, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.82% of the stock is currently owned by company insiders.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently bought and sold shares of KYMR. KBC Group NV boosted its holdings in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after buying an additional 752 shares during the period. Blue Trust Inc. boosted its stake in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after purchasing an additional 270 shares during the period. Harbor Capital Advisors Inc. increased its holdings in Kymera Therapeutics by 1.7% during the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock worth $1,649,000 after purchasing an additional 684 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Kymera Therapeutics by 212.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after purchasing an additional 95,547 shares during the period. Finally, Franklin Resources Inc. lifted its holdings in shares of Kymera Therapeutics by 35.1% in the third quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock valued at $1,356,000 after purchasing an additional 7,647 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.